CY1110506T1 - Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv - Google Patents

Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv

Info

Publication number
CY1110506T1
CY1110506T1 CY20091100955T CY091100955T CY1110506T1 CY 1110506 T1 CY1110506 T1 CY 1110506T1 CY 20091100955 T CY20091100955 T CY 20091100955T CY 091100955 T CY091100955 T CY 091100955T CY 1110506 T1 CY1110506 T1 CY 1110506T1
Authority
CY
Cyprus
Prior art keywords
treatment
hcv
disorders
cyclosporins
modified
Prior art date
Application number
CY20091100955T
Other languages
English (en)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110506T1 publication Critical patent/CY1110506T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Παρουσιάζονται μη ανοσοκατασταλτικές κυκλοσπορίνης με σύνδεση κυκλοφιλίνης, π.χ. τύπου (Ι, Ιa ή II) όπως ορίζεται στο παρόν, με χρήσιμες ιδιότητες στην πρόληψη ή τη θεραπεία των μολύνσεων της Ηπατίτιδας Γ.
CY20091100955T 2003-09-03 2009-09-16 Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv CY1110506T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
EP04764762A EP1663287B1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Publications (1)

Publication Number Publication Date
CY1110506T1 true CY1110506T1 (el) 2015-04-29

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100955T CY1110506T1 (el) 2003-09-03 2009-09-16 Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv

Country Status (30)

Country Link
US (1) US7968518B2 (el)
EP (2) EP1663287B1 (el)
JP (1) JP4688806B2 (el)
KR (1) KR101116968B1 (el)
CN (1) CN1842343A (el)
AU (2) AU2004268382A1 (el)
BR (1) BRPI0414062B8 (el)
CA (1) CA2537137C (el)
CY (1) CY1110506T1 (el)
DE (1) DE602004022061D1 (el)
DK (1) DK1663287T3 (el)
ES (1) ES2328361T3 (el)
GB (1) GB0320638D0 (el)
HK (1) HK1091732A1 (el)
HR (1) HRP20090535T1 (el)
IL (1) IL173909A (el)
IS (1) IS2917B (el)
MA (1) MA28032A1 (el)
MX (1) MXPA06002394A (el)
NO (1) NO20061479L (el)
NZ (1) NZ545495A (el)
PL (1) PL1663287T3 (el)
PT (1) PT1663287E (el)
RU (1) RU2389501C2 (el)
SG (1) SG149063A1 (el)
SI (1) SI1663287T1 (el)
TN (1) TNSN06071A1 (el)
TW (1) TWI342782B (el)
WO (1) WO2005021028A1 (el)
ZA (1) ZA200601550B (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
DE602005026294D1 (de) * 2004-07-14 2011-03-24 Novartis Ag Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
KR101309409B1 (ko) * 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006038088A1 (en) * 2004-10-01 2006-04-13 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
ATE412005T1 (de) 2004-11-22 2008-11-15 Astellas Pharma Inc Zyklosporinanalog
JP2008525458A (ja) * 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト フラビウイルス科処置用化合物
CN101076350A (zh) * 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
JP5517454B2 (ja) * 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
US8329658B2 (en) * 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
ES2557477T3 (es) * 2005-10-26 2016-01-26 Astellas Pharma Inc. Nuevos compuestos peptídicos cíclicos
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
US20100194497A1 (en) * 2006-06-02 2010-08-05 Claude Annie Perrichon Management of active electrons
CA2665415A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
US8450281B2 (en) 2007-01-04 2013-05-28 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
KR20100017547A (ko) * 2007-05-02 2010-02-16 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
EP2193807A4 (en) * 2007-08-24 2012-09-12 Univ Sapporo Medical BINDING PROTEIN AT CYCLOSPORIN A
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20130190223A1 (en) * 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
WO2010035722A1 (ja) * 2008-09-24 2010-04-01 アステラス製薬株式会社 ペプチド化合物およびその製造方法
WO2010052559A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
CN102307892A (zh) * 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
CA2751210C (en) 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CA2811700A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
CN103221053A (zh) 2010-11-30 2013-07-24 诺华有限公司 丙型肝炎病毒感染的新疗法
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2012079172A1 (en) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
KR20140007927A (ko) 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
PL2694087T3 (pl) 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
EP2760461A1 (en) 2011-09-27 2014-08-06 Novartis AG Alisporivr for treatment of hepatis c virus infection
KR20150013152A (ko) 2012-05-07 2015-02-04 노파르티스 아게 알리스포리비르를 이용한 약동학적 조절
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
EP3038626A4 (en) 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag Zyklosporine
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1319651B1 (en) 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
USRE40987E1 (en) * 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US20040033946A1 (en) 2000-10-19 2004-02-19 Futoshi Shibasaki Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
US7326801B2 (en) 2001-03-26 2008-02-05 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
ES2292809T3 (es) 2001-09-27 2008-03-16 Kyorin Pharmaceutical Co., Ltd. Derivado de sulfuro de diarilo, sal de adicion del mismo, y agente inmunosupresor.
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006038088A1 (en) 2004-10-01 2006-04-13 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物

Also Published As

Publication number Publication date
TWI342782B (en) 2011-06-01
SG149063A1 (en) 2009-01-29
MA28032A1 (fr) 2006-07-03
US20070275884A1 (en) 2007-11-29
MXPA06002394A (es) 2006-06-20
DE602004022061D1 (de) 2009-08-27
AU2008203031A1 (en) 2008-07-31
ES2328361T3 (es) 2009-11-12
CA2537137A1 (en) 2005-03-10
ZA200601550B (en) 2007-05-30
SI1663287T1 (sl) 2009-10-31
HRP20090535T1 (hr) 2009-11-30
IS8371A (is) 2006-03-24
EP1797892B1 (en) 2013-10-23
NO20061479L (no) 2006-06-02
DK1663287T3 (da) 2009-11-09
NZ545495A (en) 2010-01-29
EP1797892A1 (en) 2007-06-20
KR101116968B1 (ko) 2012-03-14
IL173909A0 (en) 2006-07-05
BRPI0414062A (pt) 2006-10-24
US7968518B2 (en) 2011-06-28
PT1663287E (pt) 2009-09-03
EP1663287B1 (en) 2009-07-15
GB0320638D0 (en) 2003-10-01
AU2004268382A1 (en) 2005-03-10
IS2917B (is) 2014-12-15
CN1842343A (zh) 2006-10-04
TNSN06071A1 (en) 2007-10-03
RU2389501C2 (ru) 2010-05-20
IL173909A (en) 2011-03-31
CA2537137C (en) 2013-05-28
HK1091732A1 (en) 2007-01-26
JP2007504260A (ja) 2007-03-01
BRPI0414062B8 (pt) 2021-05-25
JP4688806B2 (ja) 2011-05-25
KR20060132798A (ko) 2006-12-22
AU2008203031B2 (en) 2011-04-07
BRPI0414062B1 (pt) 2019-06-25
PL1663287T3 (pl) 2009-12-31
WO2005021028A1 (en) 2005-03-10
TW200524626A (en) 2005-08-01
EP1663287A1 (en) 2006-06-07
RU2006110533A (ru) 2007-10-10

Similar Documents

Publication Publication Date Title
CY1110506T1 (el) Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
EA200600498A1 (ru) Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
ATE305932T1 (de) Rapanycin29-enole
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
TW200716678A (en) Administration of HCV protease inhibitors in combination with food to improve bioavailability
DE602004016563D1 (de) Nukleierungsmittel
EA200700243A1 (ru) Способы лечения гепатита с
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
ITMI20032377A1 (it) Copolimeri del tfe.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
HRP20070012A2 (en) Immunostimulatory oligonucleotide multimers
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
TNSN07240A1 (en) Compounds for flaviviridae treatment
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
DE602006015837D1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
TN2009000135A1 (en) Use of modified cyclosporins
ATE399532T1 (de) Medizinische seife